Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INHALE 1: Amikacin Inhale for Gram-Negative Pneumonia
NCT01799993Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2013
- Primary completion
- Apr 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of amikacin liposome inhalation suspension in Gram-negative pneumonia (2 arms), sponsored by Bayer. Primary endpoint: Number of Participants Surviving Through LFU Visit. Started Apr 2013; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Gram-negative pneumonia
Beyond the preview
Go deeper on NCT01799993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01799993.